Blogs

MedTech

The role of regulatory affairs teams throughout the product lifecycle

By

Karen Cohn

March 9, 2023

4 min read

The lifecycle of a medical device

The time from when a medical device enters the market to the time it leaves, and the business and regulatory processes associated with that journey, are referred to as a product lifecycle. Regulatory affairs (RA) professionals have responsibilities at each stage of the product lifecycle and will collaborate with most sections of the business on one or more activities. In this article, we discuss the regulatory responsibilities that are typical in a large, global medical device manufacturer.

Cross collaboration with RA across the globe

The Regulatory Affairs professional at the manufacturer often does not complete regulatory activities alone. Major medical manufacturers have RA employees stationed across the globe. The international RA employees or local distributor will provide insight into their country’s regulatory requirements and will often be the individuals that have direct contact with their country’s government agency.  

For example: When a manufacturer is working on a Registration in China, the Regulatory Affairs Engineer in the U.S. may be on an 8pm call coordinating with a Regulatory Affairs Professional in China.  

Manufacturing RA Responsibilities

  • Provide details and information on the medical device.
  • Assist in-country RA in providing manufacturing SME team support on governmental questions during submission review.
  • Provide appropriate documentation from the SME teams to help complete the regulatory submission.

In-country RA Responsibilities

  • Provide insight on the in-country medical device requirements.
  • Identify Standards particular to the country.
  • Manage in-country specific submission deliverables.
  • Identify devices that need to be provided for in-country testing (if applicable).

Each major lifecycle stage – pre-market, market placement, and post-market – are discussed below.

Pre-market

Research and development

A new medical device begins with an idea for a product and an R&D process that will eventually include the quality and regulatory departments. Once designed, these devices are heavily tested to industry standards that are applicable to the device. Higher risk devices must also go through clinical trials before being brought to market. Information on compliance with standards and results from testing are included in the submission documents used to obtain market access.  

Each department plays a role in ensuring that a device and all supporting information is ready to request market entrance.

Regulatory responsibilities  

  • Identify applicable standards that will apply to the new device.
  • Collaborate with R&D to understand the functions of the new device.
  • Identify the intended use of the device.
  • Classify the device for major markets.
  • Collaborate with in-country RA for any additional device testing.

R&D responsibilities

  • Test the new device to the standards that regulatory tells them to or find a vendor that does that testing.
  • Compile the testing reports.

Business role responsibilities

  • Approve the financials for the R&D work.
  • Have an initial scope of regions where the device would be sold.

Initial business case

In parallel to the R&D preparation, a business plan will be developed by the Sales and Marketing teams, along with the Product and Project Managers (“business” teams). The business plan will detail where a product will be distributed and sold. It is incredibly important for the regulatory team to have a full understanding of this plan as early as possible so that they can research regulatory requirements and develop a regulatory plan.

The initial business case is often a back-and-forth conversation between those developing the business plan and the manufacturing and regulatory teams. The business often asks and heavily relies on the regulatory professional to describe the submission processes per country, to note any particularly challenging country for registration, and to explain why there are more requirements in some markets.

Regulatory Responsibilities

  • Notify the business of the cost of the submissions for all markets that the business intends to sell in (Market Access Submissions cost money).
  • Notify the business of the cost of man-hours on a per-registration basis.
  • Notify the business of the labeling costs.
  • Translating the manual into multiple languages.
  • Applying country-specific labeling on the package or on the device.

Business Responsibilities

  • Make good financial decisions on go-to-market.
  • Approve staffing resources for the regulatory activity.
  • Create a priority for submission activity.

Regulatory Plan

The regulatory department creates a plan of how to gain market access based on the initial business case. For large expansive launches in many countries, a regulatory plan may need to consider over 100 country requirements, which often includes a phased approach to product launches.

Regulatory responsibilities are often split between the RA resources at the manufacturer and those that are in the country in which the device is being marketed. While they vary by company, responsibilities often look something like this:

Manufacturing RA responsibilities

  • Draft the regulatory plan.
  • Provide classification for country of origin and some major markets.
  • Provide appropriate documentation from the SME teams to complete the regulatory submission.

In-country RA responsibilities

  • Provide insight on the in-country medical device requirements.
  • Classify the device per country standards.
  • Identify in-country specific submission deliverables that need manufacturing SME support.
  • Identify devices that need to be provided for in-country testing (if applicable).
  • Provide timeline estimations for international submissions.

Initial pre-market submissions

In regulated markets, a company needs to “register” their device prior to shipping, selling or marketing a device in the country. These submissions often contain confidential business information and test reports that were identified as needed in the regulatory plan. Once the device is accepted, a certificate is given to the manufacturer allowing the product to be sold in that market.

Typically, manufacturers begin by registering in their country of origin and a small subset of highly marketable countries. This phase often includes the USA and EU. Once a majority of those submissions are completed, submissions to other markets are addressed in a phased approach. There can be multiple waves of these registrations, and the entire registration process can last for months. Registration projects also often overlap for the manufacturing regulatory professional.  

Manufacturing regulatory responsibilities

  • Provide appropriate documentation from the SME teams to complete the regulatory submission.
  • Notify SME teams when support is needed.
  • Coordinate and compilate SME answers to governmental questions.
  • Update the business on the submission progress.
  • Notify the business when the submission is complete.

SME teams responsibilities

  • Provide adequate information about the device per the regulatory plan.
  • Notify the manufacturing regulatory team of any governmental questions and ask for support when needed.
  • Notify the manufacturing regulatory team of submission progress.
  • Provide SME support to develop the submission and answer governmental questions.

Business responsibilities

  • Provide funding for this activity.

Expansion to the rest of the globe

Once the initial launch is completed or near completion, submission activity now begins in every other market that the business approves to launch in. For large and expansive businesses, this launch can be over 100 countries, which can mean 100 regulatory product registrations.  

Manufacturing regulatory responsibilities

  • Provide appropriate device information to in-country RA for submission support.
  • Notify SME teams when support is needed.
  • Coordinate and compilate SME answers to governmental questions.
  • Update the business on the submission progress.
  • Notify the business when any submissions are complete.

In-country RA responsibilities

  • Complete in-country submission deliverables.
  • Identify standards particular to the country.
  • Manage in-country specific submission deliverables.
  • Identify devices that need to be provided for in-country testing (if applicable).

SME teams responsibilities

  • Provide adequate information about the device per the regulatory plan.
  • Provide SME support to develop the submission and answer governmental questions.

Rimsys provides regulatory teams with the ability to manage requirements, content plans, documents, and tasks for new registrations.

Marketing the device

Once a device is fully registered in the regulated country, it can be marketed. However, any marketing material that is created often goes through an additional legal and regulatory review as any inaccuracy can lead to fines for mislabeling the device.  

Manufacturing regulatory responsibilities

  • Coordinate with clinical to ensure claims are aligned.
  • Review marketing content to ensure regulatory compliance.
  • Notify the business when approvals are received so marketing knows when they can begin marketing the device in that country.

Marketing responsibilities

  • Create drafted content which could be product sheets, social media posts, or presentations for conferences.
  • Accept regulatory review of the marketing materials.

Market placement

Change management

Businesses add features and change medical devices all of the time. They may shift where the manufacturing facility is located, add an accessory, change a motor - all of these changes need to be assessed and submission may need to be done prior to market entry for those changes. These changes also need to be assessed on a global scale. The more countries that are involved, the more complex that process is.  

For every change, a survey is often sent out to the in-country regulatory teams, and they are often responsible for completing that assessment for their country. These are typically called impact surveys. It is then up to the RA team at the manufacturer to compile those responses and to receive approval from the business to complete any additional submissions to governments that may be required.

R&D responsibilities

  • R&D and project teams determine a change is needed.
  • Notify the manufacturing regulatory team of the upcoming change.

Manufacturing regulatory responsibilities

  • Fully understand the change that is coming from R&D.

In-country regulatory responsibilities

  • In-country specialist completes the impact survey.
  • Notify the manufacturing regulatory team if additional submission activity is needed, along with the timeline for that activity and the deliverables/support required.

Business responsibilities

  • Approve the submission activity and finance it as needed.

Renewals

After the initial submission, most countries will require a renewal submission after a set number of years to keep the device in the market. It is critical that renewal dates are tracked and managed appropriately. Missed renewal dates may require several months to over a year of work to obtain market approval again. During that time, all sales of the product are stopped.  

Manufacturing regulatory responsibilities

  • Notify the business of upcoming renewals.
  • Coordinate with in-country RA to provide documents and assist in the submission for the renewal.
  • Coordinate SME support for governmental questions if needed.

In-country regulatory responsibilities

  • Notify manufacturing regulatory in a timely manner when renewals are needed.
  • Submit the renewal to the government authority.

Business responsibilities  

  • Approve the renewals.

Rimsys simplifies global submission management with integrated tools that provide complete control over submission authoring, assembly, and publishing.

Post-market

Audits

Governments and other regulatory bodies will often audit the medical device manufacturer to ensure that they are in compliance with current regulations.  

Manufacturing regulatory responsibilities

  • Gathering device marketing registration history and facility registration for a specific set of countries to be presented by the auditor.
  • Familiarizing yourself with the registrations and recent regulatory work that has occurred in the country to be prepared for auditor's questions.  
  • Responding to auditors questions if you are on “Audit Duty”.

Quality department responsibilities  

  • Manage the facility tour.
  • Be responsible for the majority of the Quality Management System (QMS).

Research and development  

  • Provide the subject matter expert (SME) with explanations of how testing was developed for the product and the outcomes of said testing.

Post-market surveillance and reporting

Manufacturers must have ways of accepting customer complaints. In certain cases, when the complaints relate to health and safety concerns pertaining to the device, the manufacturer may need to report these complaints to their government or other countries where the device is sold.  

Correctional activities (recalls)

If a company finds a health and safety risk to their device, the company as a whole may need to gather all of the devices that are affected and either repair them or destroy them.

Obsolescence

Obsoleting a product is often a regulatory step and a submission step as well. There are many reasons to take a device out of a market; low sales, new requirements causing additional work that is not financially feasible, or new devices being available that are part of a newer generation that are safer for the user are a few reasons.  

Business responsibilities

  • Notify manufacturing RA and in-country marketing of the obsolescence of the device in the market.

Manufacturing RA responsibilities  

  • Notify in-Country RA of the obsolescence and expected date that the business will stop supporting the device in that market.

In-country RA responsibilities  

  • Submit obsolescence notification to the authority.

Learn more about how Rimsys supports the regulatory teams of some of the world’s leading Medtech companies.

Similar posts

How Smith & Nephew Repositioned Regulatory as a Strategic Commercial Partner

MedTech

RIM

How Smith & Nephew Repositioned Regulatory as a Strategic Commercial Partner

By

Caroline La

May 28, 2026

4 min read

Smith & Nephew is a global medical device manufacturerwith a broad portfolio spanning orthopedics, sports medicine, and woundmanagement, sold and registered across markets worldwide. Before Rimsys,regulatory data was scattered across spreadsheets, shared drives, anddisconnected systems.

When Smith & Nephew selected Rimsys, they deployed itenterprise-wide from day one. Executive reporting moved from manual fire drillsto real-time dashboards. Change impact assessments became faster and moreconsistent. The regulatory team made the shift from reactive compliancefunction to strategic partner to the business.

The Challenge

Regulatory data at Smith & Nephew lived in multiplespreadsheets, shared drives, SharePoint sites, emails, and disconnectedsystems. Without a centralized record, the team could not reliably trackregistration timelines, measure on-time submissions, assess change impacts, orunderstand the downstream impact of product changes across markets. Preparingexecutive reporting meant manually assembling data from multiple sources, aprocess that consumed time and introduced risk each time.

The Solution

Smith & Nephew selected Rimsys for its configurable, notcustomized, platform: an intuitive user interface, centralized submissionmanagement, robust metrics, change assessment capabilities, and UDI supportwith machine-to-machine transmission. Rimsys’ interconnected modulearchitecture linked products, registrations, projects, change assessments, andUDI in a centralized location.

Rather than piloting in one business unit, Smith &Nephew deployed Rimsys across the entire regulatory organization from day one.The decision was deliberate: a partial deployment would have preserved thefragmentation. Enterprise-wide adoption established consistent metrics,standardized processes, and a single source of truth from the start.

The Results

Executive and board reporting, previously built from manualdata pulls, now flows directly from Rimsys in real time. What had been adisruptive, recurring effort is now a routine view. Leadership has thevisibility to make faster, more confident decisions, and the regulatory team isno longer pulled into reporting fire drills.

Change management has also been transformed. Direct linkagebetween products, registrations, and projects means impact assessments arefaster and less dependent on individual knowledge. UDI operations havesimilarly improved: machine-to-machine transmission has reduced manual uploadsand centralized DI record visibility supports global UDI requirements.

The most significant shift is strategic. With centralizedregulatory intelligence and real-time data, Smith & Nephew’s regulatoryteam now actively supports commercial planning: informing budget cycles,guiding renewal and launch sequencing, and advising on regulatory pathways toaccelerate market entry. Regulatory is no longer a downstream compliancefunction. It is a business partner.

Smith & Nephew now runs four modules across its RIM operation:

  • Registrations— Centralized license tracking across 250 countries and 30+ business units
  • Change Assessments— Direct product-registration linkage for faster, consistent impact assessments
  • Executive Reports— Real-time dashboards replacing manual data pulls and board reporting fire drills
  • UDI— Machine-to-machine transmission reducing manual uploads across global markets

Take this to your team

If you’re evaluating how to modernize RIM operations at scale, the Smith & Nephew case study is a practical reference to share internally. It covers the full implementation story, module breakdown, and results data in a format built for stakeholder conversations.

Download the Case Study

MedTech

RIM

How Philips Scaled Active Product Registrations More Than 20x

By

Caroline La

May 21, 2026

4 min read

Philips Healthcare operates one of the largest regulatory portfolios in global MedTech: products registered across 250 countries, with a footprint that grows with every acquisition. Before Rimsys, that complexity was managed through email and spreadsheets. Submission packages moved through inboxes with no audit trail, no performance data, and no reliable view of where products were authorized to ship.

Philips selected Rimsys in 2022 as the enterprise RIM platform to bring regulatory order to that complexity. Since go-live, active product registrations have scaled more than 20x, user adoption has doubled in the last six months, and the regulatory affairs function now operates from a single source of truth spanning the entire enterprise.

The Challenge

Without structured data, Philips could not measure regulatory performance, track license expiration across the portfolio, or identify where submission work was stalling. Every acquisition made it worse: incoming business units arrived with their own workflows and systems, absorbing more fragmentation rather than resolving it.

The Solution

Philips evaluated multiple platforms against requirements built with both market-facing and business regulatory affairs teams. Rimsys won on two dimensions: an interface that made complex product and registration data immediately visible, and more enterprise-ready features than competing platforms at the right price point.

Philips went live with Rimsys Registrations and Submissions modules in July 2022. The team deployed platform experts for train-the-trainer sessions and launched regular drop-in sessions where users could ask questions and surface issues. Standing up a dedicated Regulatory Operations team focused exclusively on rest-of-world registration accelerated adoption further.

When an early business unit pushed back on workflow efficiency, Philips and Rimsys worked through it together. A hands-on process walkthrough identified exactly what needed to change, a resolution plan was shared, and that transparency and collaboration became the foundation for sustained user buy-in across the enterprise.

The Results

Since go-live, Philips has scaled active product registrations more than 20x, with further growth already underway. What started as a single deployment now spans 30+ business units across 250 countries, with Rimsys serving as the single source of truth for regulatory data across the enterprise, including businesses acquired since implementation.

For the first time, Philips can measure its own regulatory performance. KPIs flow directly from the platform, giving leadership real-time visibility into registration health. When anomalies surface, they drive data correction and user training, closing gaps that previously went undetected until they affected revenue.

Now with Rimsys AI-assisted Submissions and Regulatory Intelligence now in use, Philips expects to accelerate further: reducing administrative burden so skilled regulatory professionals can focus on strategy.

Philips now runs four modules across its RIM operation:

  • Registrations— Centralized license tracking across 250 countries and 30+ business units
  • Submissions— AI-assisted submission workflows replacing email-based package management
  • Intelligence— Real-time KPI dashboards giving leadership visibility into registration health
  • Standards— Essential Principles and standards tracking aligned to global market requirements

Take this to your team

If you’re evaluating how to modernize RIM operations at scale, the Philips Healthcare case study is a practical reference to share internally. It covers the full implementation story, module breakdown, and results data in a format built for stakeholder conversations.

Download the Case Study

AI

RIM

UDI

EUDAMED

MedTech

What RAPS Euro Convergence 2026 Told Us About the Future of MedTech Regulation

By

Caroline La

May 12, 2026

4 min read

Last week, the MedTech regulatory community gathered in Lisbon for RAPS Euro Convergence 2026: nearly 100 sessions, hundreds of professionals, and one overriding theme: transformation.The European regulatory landscape is shifting faster than it has in two decades, and the pressure is on every RA team to keep pace.

We were there. And here is what we took away.

The Dominant Signal: Change Is Accelerating

For MedTech manufacturers, the immediate reality is demanding. MDR 2.0 is advancing. The EU AI Act is creating new compliance obligations for software-enabled devices. EUDAMED continues to mature. And teams are being asked to absorb all of this while still meeting existing registration and renewal deadlines.

The practical implication is clear: RA functions that rely on manual tracking, disconnected spreadsheets, and tribal knowledge are being outrun by the pace of change. Across the industry, teams are moving from talking about AI to actively experimenting with it, using it to handle the volume and complexity that manual processes simply cannot absorb. The teams emerging as strategic forces are the ones who have connected, real-time regulatory infrastructure and are putting AI to work within it.

AI Is No Longer Optional Thinking

The conversation at Euro Convergence made one thing clear: AI has moved from future-state to present-tense. Regulatory professionals were encouraged to embrace AI while maintainingaccountability for the outcome and challenging the algorithms.

" Our role is to make sure that the AI does the right interpretations appropriate to our products, to our business."

— João Martins, Director of Regulatory Affairs at Abbott at RAPS Euro Convergence 2026 Opening Plenary

That framing resonates deeply with how we have built AI into Rimsys. The goal was never to replace regulatory judgment; it is to amplify it. Rimsys AI is domain-specific, built on the regulatory data structures and logic that reflect real-world requirements, country-specific nuances, and product context. It proposes, analyzes, and alerts. Your team reviews, approves, and decides.

For teams that are ready to accelerate, Rimsys AI accelerates regulatory intelligence monitoring and submission authoring, removing the repetitive, detail-heavy work so skilled professionals can focus on strategy, market expansion, and the higher-order decisions that increasingly complex regulations demand.

"As future regulators, we will need to be scientifically strong, comfortable with complexity, open to innovation, and also be able to work in increasingly complex environments."

— Rui Santos Ivo, President of Portugal's National Authority of Medicines and Health Products (INFARMED) and chair of the EMA management board, RAPS Euro Convergence 2026 Opening Plenary

MDR 2.0: Reform With Guardrails

A panel of experts representing regulators, industry, and notified bodies gave their views on the proposed revision of the EU Medical Device Regulation at the conference. While their sentiments were largely supportive, notified body representatives urged the European Commission to maintain proactive surveillance of devices to protect patients.

The discussion acknowledged the complexity of balancing reform with patient safety. Simplification and innovation go hand in hand, though if it is overly complicated or overly simplified, it becomes difficult to innovate. Structured dialogues in MDR/IVDR will provide transparency and predictability for manufacturers, especially in early product development.

Regulatory Workflows Cannot Be an Afterthought

A recurring observation across sessions was that MDR 2.0, EUDAMED, and the EU AI Act are only as effective as the operational workflows behind them. Structured dialogues, risk-proportionate pathways, and submissions all require teams to move quickly with accurate, up-to-date product data. That is simply not possible when that data lives across email threads, spreadsheets, and disconnected systems.

The workflows that came up most in Lisbon (change control, renewals, new product introductions, and registration management) are exactly the areas where manual processes create the most risk. A missed renewal. A design change that triggers 40 country-level impact assessments with no system to coordinate them. A registration record that no one has updated since the last audit.

Rimsys keeps these workflows connected and proactive. Renewal expiration reminders fire before deadlines become a risk. Change control impact surveys are configurable to your SOPs, so teams can assign tasks and coordinate work across regions without relying on someone to manually track progress. New product introductions move faster because previous submission content can be reused across markets. Target market data, registration history, and approval status are already centralized, so teams are building on existing work rather than starting from scratcheach time.

The result is regulatory operations that reduce time to market by weeks to months, not add to it. Access information in seconds rather than hours. Regulatory release authorization in minutes rather than weeks. More than 90% reduction in regional regulatory reporting time. These are not projections. They are outcomes reported by Rimsys customers operating in exactly the kind of complex, multi-market environments that dominated the conversation in Lisbon.

The Regulatory Professional Is Evolving

Perhaps the most striking thread across sessions was the evolution of the RA function itself. Regulatory work was once seen mainly in terms of compliance procedures and submissions. Today, the profession is much broader than that.

This evolution is exactly the transition Rimsys is designed to support. When regulatory data is centralized, connected, and visible in real time, RA teams stop spending their days chasing down registration status and start contributing to commercial strategy: market expansion decisions, launch sequencing, change control planning, and executive-level risk communication.

The heart of regulatory operations is not a filing cabinet. It is a living, connected system that elevates the entire function.

What It All Points To

RAPS Euro Convergence 2026 made one thing clear: the organizations that will thrive are those who have invested in regulatory infrastructure that can absorb change without breaking. Rimsys is the platform built for exactly this moment: enterprise-grade, intuitive enough for global teams to actually use, and trusted by 6 of the top 12 global MedTech manufacturers worldwide.

Book a conversation with our team

I agree to the privacy policy including to Rimsys using my contact details to contact me for marketing purposes.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Hand holding smartphone showing email app with 12 unread messages notification.